The small molecule inhibitor 3PO is a modulator of neutrophil metabolism, ROS production, and NET release
Clinical and Experimental Immunology · 21.01.2025 · 219 (1)
DOI: 10.1093/cei/uxaf012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 19.02.2025. Verfasst von Michele Fresneda Alarcon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Neutrophils, Reactive Oxygen Species, Extracellular Traps, Phosphofructokinase-2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Versus Arthritis and Masonic Charitable Fund, University of Liverpool CIMA MRes Scholarship, Dunhill Medical Trust.
Abstract (Originalsprache)
Neutrophils are key effector leukocytes of the innate immune system and play a pivotal role in defending the host against microbial infections. Recent studies have identified a crucial link between glycolysis and neutrophil cellular functions. Using human neutrophils, we have investigated the intricate relationship between glycolysis, extracellular glucose availability, and the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), in the regulation of reactive oxygen species (ROS) and neutrophil extracellular trap (NET) production. We have identified that PFKFB3 is elevated in rheumatoid arthritis (RA) neutrophils and that the small molecule PFKFB3 inhibitor 3PO is a key regulator of neutrophil ROS and NET production. 3PO blocked the production of ROS and NETs in a dose-dependent manner in both RA and healthy neutrophils (P < 0.01), and RA neutrophils were more sensitive to lower concentrations of 3PO. Bacterial killing was only partially inhibited by 3PO, and the proportion of live neutrophils after 24 h incubation was unchanged. Using NMR metabolomics, we identified that 3PO increases the concentration of lactate, phenylalanine, and L-glutamine in neutrophils, as well as significantly decreasing intracellular glutathione (adj. P-value < 0.05). We also demonstrated that RA neutrophils produce ROS and NETs in culture conditions which mimic the low glucose environments encountered in RA synovial joints. Our results also suggest that 3PO may have molecular targets beyond PFKFB3. By dissecting the intricate interplay between metabolism and neutrophil effector functions, this study advances the understanding of the molecular mechanisms governing pro-inflammatory neutrophil responses and identifies 3PO as a potential therapeutic for conditions characterized by dysregulated neutrophil activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Institute of Systems, Molecular and Integrative Biology (ISMIB), Liverpool Head and Neck Centre, University of Liverpool, Liverpool, UK.
- Institute of Systems Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
- High Field NMR Facility, Liverpool Shared Research Facilities, University of Liverpool, Liverpool, UK.
ORCID-Profile: Helen L Wright
Förderung
- Versus Arthritis and Masonic Charitable Fund
- University of Liverpool CIMA MRes Scholarship
- Dunhill Medical Trust
- University of Liverpool PhD Scholarship
- Connect Immune Research
- The Lorna & Yuti Chernajovsky Biomedical Research Foundation
- Versus Arthritis Career Development Fellowship
- MRC
Zitieren
APA
Fresneda Alarcon, M., Abdullah, G. A., Nolan, A., Linford, C., Meschis, M. M., Cross, A. L., Sellin, A., Phelan, M. M., & Wright, H. L. (2025). The small molecule inhibitor 3PO is a modulator of neutrophil metabolism, ROS production, and NET release. Clinical and Experimental Immunology, 219(1). https://doi.org/10.1093/cei/uxaf012
Vancouver
Fresneda Alarcon M, Abdullah GA, Nolan A, Linford C, Meschis MM, Cross AL, et al. The small molecule inhibitor 3PO is a modulator of neutrophil metabolism, ROS production, and NET release. Clinical and Experimental Immunology. 2025;219(1). doi:10.1093/cei/uxaf012
BibTeX
@article{FresnedaAlarcon2025,
author = {Fresneda Alarcon, Michele and Abdullah, Genna Ali and Nolan, Andy and Linford, Christina and Meschis, Maria Martina and Cross, Andrew L and Sellin, Andrew and Phelan, Marie M and Wright, Helen L},
title = {The small molecule inhibitor 3PO is a modulator of neutrophil metabolism, ROS production, and NET release},
journal = {Clinical and Experimental Immunology},
year = {2025},
volume = {219},
number = {1},
doi = {10.1093/cei/uxaf012}
}
EUVIMED